open access

Vol 94, No 3 (2023)
Research paper
Published online: 2022-03-07
Get Citation

Effect of mucinous differentiation in endometrioid type endometrial cancers on prognosis

Bahadir Saatli1, Orkun Ilgen2, Selim Kandemir1, Seda Eryigit3, Meral Koyuncuoglu3, Cagnur Ulukus3, Erkan Cagliyan1
·
Pubmed: 35315013
·
Ginekol Pol 2023;94(3):183-187.
Affiliations
  1. Dokuz Eylul University School of Medicine Department of Obstetrics and Gynecology, Izmir, Turkey
  2. Dokuz Eylul University School of Medicine Department of Obstetrics and Gynecology, Izmir, Türkiye
  3. Dokuz Eylul University School of Medicine Department of Pathology, Izmir, Turkey

open access

Vol 94, No 3 (2023)
ORIGINAL PAPERS Gynecology
Published online: 2022-03-07

Abstract

Objectives: To evaluate the influence of mucinous differentiation in endometrioid endometrial cancer regarding spread and prognosis.

Material and methods: Endometrioid endometrial cancer cases between 2015 and 2020 were collected retrospectively and divided into two groups according to the cytoplasmic mucin including. Prognostic factors and cancer spread related parameters were evaluated.

Results: A total of 219 patients were enrolled in this study. One hundred twenty-two (55.7%) were endometrioid and 97 (44.3%) were in the mucinous differentiated endometrioid catagory. Age was similar between the groups (59.3 vs 58.7, p = 0.62), however, grade 3 lesions were more frequent in endometrioid type endometrial cancer (8.7% vs 1.4%, p < 0.01). Poor prognostic factors including myometrial invasion, lymphovascular space invasion (LVSI), lymph node metastases, peritoneal cytology, endocervical involvement, and stage were not significantly different between groups (p = 0.23, p = 0.49, p = 0.40, p = 0.15, p = 0.17, p = 0.55). The median overall survival time of endometrioid and mucinous differentiated endometrioid type endometrial cancer patients was determined 88.5 and 96.8 months, respectively (p = 0.46).

Conclusions: Mucinous differentiation in the endometrioid type of endometrial cancer does not seem to affect the prognosis in endometrioid endometrial cancer patients.

Abstract

Objectives: To evaluate the influence of mucinous differentiation in endometrioid endometrial cancer regarding spread and prognosis.

Material and methods: Endometrioid endometrial cancer cases between 2015 and 2020 were collected retrospectively and divided into two groups according to the cytoplasmic mucin including. Prognostic factors and cancer spread related parameters were evaluated.

Results: A total of 219 patients were enrolled in this study. One hundred twenty-two (55.7%) were endometrioid and 97 (44.3%) were in the mucinous differentiated endometrioid catagory. Age was similar between the groups (59.3 vs 58.7, p = 0.62), however, grade 3 lesions were more frequent in endometrioid type endometrial cancer (8.7% vs 1.4%, p < 0.01). Poor prognostic factors including myometrial invasion, lymphovascular space invasion (LVSI), lymph node metastases, peritoneal cytology, endocervical involvement, and stage were not significantly different between groups (p = 0.23, p = 0.49, p = 0.40, p = 0.15, p = 0.17, p = 0.55). The median overall survival time of endometrioid and mucinous differentiated endometrioid type endometrial cancer patients was determined 88.5 and 96.8 months, respectively (p = 0.46).

Conclusions: Mucinous differentiation in the endometrioid type of endometrial cancer does not seem to affect the prognosis in endometrioid endometrial cancer patients.

Get Citation

Keywords

mucinous differantiation; endometrioid endometrial cancer; endometrial cancer prognosis

About this article
Title

Effect of mucinous differentiation in endometrioid type endometrial cancers on prognosis

Journal

Ginekologia Polska

Issue

Vol 94, No 3 (2023)

Article type

Research paper

Pages

183-187

Published online

2022-03-07

Page views

2689

Article views/downloads

724

DOI

10.5603/GP.a2021.0258

Pubmed

35315013

Bibliographic record

Ginekol Pol 2023;94(3):183-187.

Keywords

mucinous differantiation
endometrioid endometrial cancer
endometrial cancer prognosis

Authors

Bahadir Saatli
Orkun Ilgen
Selim Kandemir
Seda Eryigit
Meral Koyuncuoglu
Cagnur Ulukus
Erkan Cagliyan

References (14)
  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
  2. Göksedef BPÇ, Akbayır O, Corbacıoğlu A, et al. Comparison of preoperative endometrial biopsy grade and final pathologic diagnosis in patients with endometrioid endometrial cancer. J Turk Ger Gynecol Assoc. 2012; 1;13(2): 106–110.
  3. Mao W, Wei S, Yang H, et al. Clinicopathological study of organ metastasis in endometrial cancer. Future Oncol. 2020; 16(10): 525–540.
  4. Li Y, Cong P, Wang P, et al. Risk factors for pelvic lymph node metastasis in endometrial cancer. Arch Gynecol Obstet. 2019; 300(4): 1007–1013.
  5. Chan JK, Kapp DS, Cheung MK, et al. Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. Am J Obstet Gynecol. 2008; 198(2): 216.e1–216.e5.
  6. Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control. 2009; 16(1): 46–52.
  7. Sumangala G, Premalatha TS, Kulkarni K, et al. Uterine Papillary Serous Carcinoma—Still an Enigma? Indian J Gynecol Oncol. 2017; 15(1): 11.
  8. Duzguner S, Turkmen O, Kimyon G, et al. Mucinous endometrial cancer: Clinical study of the eleven cases . North Clin Istanb. 2019; 3;7(1): 60–64.
  9. Kim KR, Robboy SJ. Mucinous Adenocarcinoma of the Endometrium. In: Deavers M, Coffey D. ed. Precision Molecular Pathology of Uterine Cancer. Molecular Pathology Library, vol 11. Springer, Cham 2017: 143–154.
  10. Galic V, Schiavone MB, Herzog TJ, et al. Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. Cancer Invest. 2013; 31(7): 500–504.
  11. Musa F, Huang M, Adams B, et al. Mucinous histology is a risk factor for nodal metastases in endometrial cancer. Gynecol Oncol. 2012; 125(3): 541–545.
  12. Gungorduk K, Ozdemir A, Ertas IE, et al. Is mucinous adenocarcinoma of the endometrium a risk factor for lymph node involvement? A multicenter case-control study. Int J Clin Oncol. 2015; 20(4): 782–789.
  13. Worley MJ, Davis M, Berhie SH, et al. Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol. 2014; 135(1): 54–57.
  14. Abdulfatah E, Sakr S, Morris RT, et al. Mucinous differentiation is predictive of improved outcomes in low-grade endometrioid carcinoma. Gynecol Oncol. 2017; 1(145): 121–122.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl